Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2002

View Archived Issues

Company Profile: Entomed

U.S. launch of Paremyd scheduled for March

Aricept associated with significant benefits in the treatment of vascular dementia

Forest receives approvable letter for Lexapro in major depressive disorder

Iressa under regulatory review in two major markets for NSCLC

Phase IIb results reported for OvaRex in metastatic ovarian cancer

Argenta Discovery and Lundbeck collaborate on CNS program

Synt:em collaborates with Baxter to develop monoclonal antibody mimetics

Novirio research consortium receives grant for antiflavivirus drug candidate development

Schering AG and Mologen to develop cell-based therapies

First Plantibodies candidate heads for clinical testing

Chemokine CCR1 receptor antagonist effective in mouse model of renal fibrosis

Preparation and use of new series of PDE5 inhibitors

Acylphenylurea derivatives effective as inhibitors of glycogen phosphorylase according to Aventis

Novel caspase inhibitors identified at Vertex

Pfizer team synthesizes selective adenosine A2A receptor agonists

Benzamide-containing compounds that act as ligands of thyroid hormone receptor beta

Preparation and use of purine derivatives with antiviral activity claimed

Rituximab + CHOP as a new drug combination for aggressive NHL

TKT's Fabry's disease enzyme replacement therapy available for use in E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...